---
figid: PMC5602476__ott-10-4535Fig1
figlink: /pmc/articles/PMC5602476/figure/f1-ott-10-4535/
number: Figure 1
caption: 'EML4–ALK pathways and the mechanism of resistance to crizotinib.Notes: (A)
  Crizotinib binds to the ALK-TKI domain of the EML4–ALK fusion protein and inhibits
  downstream signaling of canonical oncogenic pathways such as the PI3K pathway and
  RAS pathway. (B) Acquired resistance to crizotinib occurs after crizotinib treatment
  due to mutations in ALK. In addition, amplification of C-KIT and/or increased EGFR
  signaling can cause progression, independent of EML4–ALK. Cells remain ALK driven,
  and alectinib successfully improves PFS by inhibiting several ALK mutations that
  cause crizotinib resistance.Abbreviations: EML4–ALK, echinoderm microtubule-associated
  protein-like–anaplastic lymphoma kinase; ALK, anaplastic lymphoma kinase; TKI, tyrosine
  kinase inhibitor; PI3K, phosphoinositide 3-kinase; RAS, rat sarcoma protein; C-KIT,
  proto-oncogene C-KIT; EGFR, epidermal growth factor receptor; PFS, progression-free
  survival; mTOR, mechanistic target of rapamycin; Mek, mitogen-activated protein
  kinase; Erk, extracellular signal-regulated kinase.'
pmcid: PMC5602476
papertitle: 'Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung
  cancer: clinical impact of alectinib.'
reftext: Ittai B Muller, et al. Onco Targets Ther. 2017;10:4535-4541.
pmc_ranked_result_index: '47083'
pathway_score: 0.9645991
filename: ott-10-4535Fig1.jpg
figtitle: 'Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung
  cancer: clinical impact of alectinib.'
year: '2017'
organisms: Homo sapiens
ndex: 53edee74-deaa-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5602476__ott-10-4535Fig1.html
  '@type': Dataset
  description: 'EML4–ALK pathways and the mechanism of resistance to crizotinib.Notes:
    (A) Crizotinib binds to the ALK-TKI domain of the EML4–ALK fusion protein and
    inhibits downstream signaling of canonical oncogenic pathways such as the PI3K
    pathway and RAS pathway. (B) Acquired resistance to crizotinib occurs after crizotinib
    treatment due to mutations in ALK. In addition, amplification of C-KIT and/or
    increased EGFR signaling can cause progression, independent of EML4–ALK. Cells
    remain ALK driven, and alectinib successfully improves PFS by inhibiting several
    ALK mutations that cause crizotinib resistance.Abbreviations: EML4–ALK, echinoderm
    microtubule-associated protein-like–anaplastic lymphoma kinase; ALK, anaplastic
    lymphoma kinase; TKI, tyrosine kinase inhibitor; PI3K, phosphoinositide 3-kinase;
    RAS, rat sarcoma protein; C-KIT, proto-oncogene C-KIT; EGFR, epidermal growth
    factor receptor; PFS, progression-free survival; mTOR, mechanistic target of rapamycin;
    Mek, mitogen-activated protein kinase; Erk, extracellular signal-regulated kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - AKT1
  - KRAS
  - KIT
  - EGFR
  - PIK3CD
  - AKT3
  - PIK3R3
  - HRAS
  - PIK3R5
  - MAP2K1
  - PIK3CG
  - MAPK3
  - PIK3CB
  - MAPK1
  - NRAS
  - PIK3CA
  - PIK3R6
  - PIK3R4
  - MTOR
  - MAP2K2
  - Cancer
  - Lung cancer
genes:
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: C-KIT
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Mek
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: Erk
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Erk
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: Mek
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
